Please login to the form below

Not currently logged in
Email:
Password:

cardiovascular disease

This page shows the latest cardiovascular disease news and features for those working in and with pharma, biotech and healthcare.

Pfizer takeover rumour ignites Amarin shares

Pfizer takeover rumour ignites Amarin shares

fish oil product Vascepa in cardiovascular disease prevention. ... which found that the drug cut the risk of heart attacks and stroke by 25% in high-risk cardiovascular patients.

Latest news

  • Roche enters NASH race with deal to buy Jecure Roche enters NASH race with deal to buy Jecure

    Inflammation is considered to be a trigger for the liver damage that characterises the disease. ... Feldstein – sits apart from rival therapies and could have applications beyond NASH in other inflammatory disorders gout including inflammatory bowel

  • Lilly trumpets Trulicity heart data in face-off with Novo Nordisk Lilly trumpets Trulicity heart data in face-off with Novo Nordisk

    cardiovascular disease, says Lilly, as less than a third (31%) of patients had established heart disease at enrolment. ... 2 diabetes with established cardiovascular disease based on data from the EMPA-REG trial, and all the big diabetes players have

  • Novartis: pipeline will generate 60 filings in three years Novartis: pipeline will generate 60 filings in three years

    oral dosing – as well as VEGF inhibitor brolucizumab (RTH258) for neovascular age-related macular degeneration (nAMD), anti-P-selectin antibody crizanlizumab (SEG101) for sickle cell disease, and canakinumab (ACZ885), an ... Last month the company

  • Novartis and Pfizer to collaborate on NASH combinations Novartis and Pfizer to collaborate on NASH combinations

    Non-Alcoholic Steatohepatitis ( NASH) has been ‘the next big thing’ for a few years now, with many big pharma licensing deals for new treatments for the fatty liver disease, and racing ... 2 diabetes and cardiovascular disease.

  • NICE says no to AZ and Vifor’s rival hyperkalaemia drugs NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

    Most common in patients with poor kidney function, heart failure or liver disease, hyperkalemia can be fatal, and patients have had few options for treatment until now. ... The companies argue that this exposes patients to cardiovascular disease risk,

More from news
Approximately 15 fully matching, plus 226 partially matching documents found.

Latest Intelligence

  • New models of NHS care – new models of pharma response? New models of NHS care – new models of pharma response?

    The region is now adopting population health models for musculoskeletal (MSK) respiratory disease, diabetes and cardiovascular disease. ... Echoing James Roach’s sentiment, she said: “Please don't wait to be asked, but make sure you're coming to us

  • The threat of antimicrobial resistance The threat of antimicrobial resistance

    the low commercial value placed on antibiotic drugs compared to more lucrative sectors such as cardiovascular disease and cancer. ... By January 2018, the US Centers for Disease Control and Prevention had reported 29 cases of MCR resistance identified

  • Pharma deals continue to slide Pharma deals continue to slide

    J) and Xoma has licensed its interleukin 1 beta intellectual property for cardiovascular disease to Novartis plus a developed product where development had stopped. ... Gevokizumab plus IP for use of IL-1 beta targeting antibodies for cardiovascular

  • Perfecting the pharmaceutical pipeline with AI Perfecting the pharmaceutical pipeline with AI

    keeps timelines long and expensive.  This has a knock-on effect for research around rare disease types specifically.  Financial cost and ROI remain big factors for pharmaceutical companies in determining what ... For example, a drug being used for

  • The EarthWorks: New ways to improve patient care The EarthWorks: New ways to improve patient care

    Keeping people well and preventing illness. Technology is only interesting socially when it is boring technologically; we have to have scale to begin to prevent disease on a population level. ... cardiovascular disease and transplantation.

More from intelligence
Approximately 0 fully matching, plus 21 partially matching documents found.

Latest appointments

  • Sanifit appoints Alexander Gold chief medical officer Sanifit appoints Alexander Gold chief medical officer

    Alex arrives here with first class operational and clinical development expertise in novel drug therapies, targeting cardiovascular and metabolic disease and kidney disease amongst others.

  • Leading Edge bolsters its delivery team Leading Edge bolsters its delivery team

    Francesca Worthington joins the group as an account manager after working across a variety of medical communication programmes and in a number of therapy areas, including haematology, ophthalmology, cardiovascular disease and

  • MyoKardia appoints COO and medical affairs VP MyoKardia appoints COO and medical affairs VP

    Prior to this, Dr Lee was therapeutic area head for cardiovascular, metabolic, respiratory and infectious disease programmes at Genentech. ... Their expertise and counsel will broaden our base of leadership and support our mission to change the world for

  • The Medicines Company appoints Biogen's Tony Kingsley The Medicines Company appoints Biogen's Tony Kingsley

    He will also serve at the company, which focuses on serious infectious disease care, acute cardiovascular care, and surgery and perioperative care, as its president, taking over from Glenn Sblendorio, who

  • MedImmune appoints Dr Christopher Rhodes MedImmune appoints Dr Christopher Rhodes

    Will head cardiovascular and metabolic diseaseresearch for the AZ unit. AstraZeneca's biologics research and development arm MedImmune has appointed Dr Christopher Rhodes as vice president, cardiovascular and metabolic disease (CVMD) ... exciting time

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 15 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
BASTARD . LONDON

BASTARD . LONDON collaborates with you to amplify brand ideas into a visual brand language that resonates and engages with...

Latest intelligence

Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....

Infographics